Score Overview
Explore the 2021 public Archive ranking →
Where Amylyx Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AMLX does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-13 | $ 26.85 | — |
1 Year2025-10-13 | $ 14.12 | 90.16% |
All Time2022-01-07 | $ 18.07 | 48.59% |
| Period | Last Price2026-10-13 | 1 Year2025-10-13 | All Time2022-01-07 |
|---|---|---|---|
| Price | $ 26.85 | $ 14.12 | $ 18.07 |
| Return | — | 90.16% | 48.59% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 152M | $ 250M |
| 2025 | $ 0.00 | -$ 144M | $ 316M |
| 2024 | $ 87M | -$ 301M | $ 176M |
| 2023 | $ 380M | $ 49M | $ 371M |
| IPO2022 | $ 22M | -$ 198M | $ 346M |
Amylyx Pharmaceuticals Inc fundamental performance
Across Amylyx Pharmaceuticals Inc's full reported history, from 2022 to 2025, revenue declined from $ 22M to $ 0.00 and net income went from -$ 198M to -$ 144M. Revenue increased in 25% of the years measured; net income in 50%.
Membership
Explore AMLX with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,125 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
